Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.626
Abstract: The pharmacokinetics (PK) and safety of single‐inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) after single and repeat dosing in healthy Chinese adults were assessed. In this open‐label study (NCT02837380), subjects received once‐daily FF/UMEC/VI 100/62.5/25 µg on day 1… read more here.
Keywords: healthy chinese; furoate umeclidinium; repeat; chinese adults ... See more keywords
Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial
Sign Up to like & getrecommendations! Published in 2017 at "Advances in Therapy"
DOI: 10.1007/s12325-017-0604-x
Abstract: IntroductionChronic obstructive pulmonary disease is associated with a high healthcare resource and cost burden. Healthcare resource utilization was analyzed in patients with symptomatic chronic obstructive pulmonary disease at risk of exacerbations in the FULFIL study.… read more here.
Keywords: resource utilization; healthcare resource; furoate umeclidinium; budesonide formoterol ... See more keywords
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Sign Up to like & getrecommendations! Published in 2017 at "Respiratory medicine"
DOI: 10.1016/j.rmed.2016.12.001
Abstract: BACKGROUND The contribution of fluticasone furoate (FF) on lung function in the FF/vilanterol (VI) 100/25 μg combination has been demonstrated numerically, but not statistically. METHODS This multicentre, randomised, double-blind, controlled trial (GlaxoSmithKline study number 200820; clinicaltrials.gov… read more here.
Keywords: contribution; vilanterol; fluticasone furoate; lung function ... See more keywords
Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
Sign Up to like & getrecommendations! Published in 2017 at "The Lancet"
DOI: 10.1016/s0140-6736(17)32397-8
Abstract: BACKGROUND Evidence for management of asthma comes from closely monitored efficacy trials done in highly selected patient groups. There is a need for randomised trials that are closer to usual clinical practice. METHODS We did… read more here.
Keywords: usual care; fluticasone furoate; furoate; furoate vilanterol ... See more keywords
A Comparison of the Efficacy of Once-Daily Fluticasone Furoate/Vilanterole with Twice-Daily Fluticasone Propionate/Salmeterol in Elderly Asthmatics.
Sign Up to like & getrecommendations! Published in 2018 at "Drug research"
DOI: 10.1055/s-0043-118536
Abstract: BACKGROUND Asthma in the elderly population has been focused because it affects quality of life and results in a higher hospitalization rate and mortality. Fluticasone furoate (FF)/vilanterole (VI) is a novel inhaled corticosteroids (ICS)/long-acting β2… read more here.
Keywords: treatment; twice daily; furoate vilanterole; fluticasone furoate ... See more keywords
Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Asthma"
DOI: 10.1080/02770903.2022.2051547
Abstract: Abstract Background In recent years, the combination of fluticasone furoate and vilanterol (FF/VI) has emerged as an alternative therapy, since it is administered every 24 h, in contrast to other ICS/LABAs such as fluticasone propionate plus… read more here.
Keywords: fluticasone furoate; cost; vilanterol; persistent asthma ... See more keywords
Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Respiratory Medicine"
DOI: 10.1080/17476348.2017.1386564
Abstract: ABSTRACT Introduction: Current national and international guidelines for the management of patients with stable chronic obstructive pulmonary disease (COPD) recommend the use of inhaled long-acting bronchodilators, inhaled glucocorticoids and their combinations for maintenance treatment of… read more here.
Keywords: chronic obstructive; obstructive pulmonary; treatment; pulmonary disease ... See more keywords
Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of aerosol medicine and pulmonary drug delivery"
DOI: 10.1089/jamp.2016.1322
Abstract: BACKGROUND The unit dose dry powder inhaler (UD-DPI) is being considered as an alternative inhaler platform that, if developed, has the potential to improve access to inhaled respiratory medicines in developing countries. AIM This study… read more here.
Keywords: dry powder; powder inhaler; inhaler; dpi ... See more keywords
In Vitro Drug Delivery of a Fixed-Dose Combination of Fluticasone Furoate/Umeclidinium/Vilanterol from a Dry Powder Inhaler
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Aerosol Medicine and Pulmonary Drug Delivery"
DOI: 10.1089/jamp.2021.0061
Abstract: Background: Dry powder inhalers (DPIs) require patients to impart sufficient energy through inhalation to ensure adequate dose emission, medication deaggregation, and resultant particle sizes suitable for lung deposition. There is an ongoing debate regarding the… read more here.
Keywords: dose emission; dry powder; flow rates; delivery ... See more keywords